Patents Examined by My-Chau T Tran
  • CETP inhibitors for therapeutic use
    Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
    Patent number: 10709690
    Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: July 14, 2020
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Tianxin Yang
  • Prenylated hydroxystilbenes
    Patent number: 10696615
    Abstract: A method for treating cancer can include administering a therapeutically effective amount of a compound of formula (Ia): or pharmaceutically acceptable salts or solvates thereof, wherein R1a, R1b, R1c, R1d, R2, and R3 are as defined, and A----B is selected from CH?CH, CH?CH(CH2)pCH2, or CH2—CH2(CH2)pCH2, and where p is 1 or 2.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 30, 2020
    Assignee: The University of Sydney
    Inventors: Colin Charles Duke, Van Hoan Tran, Rujee Kyokajee Duke
  • Methods of treating and preventing graft versus host disease
    Patent number: 10695350
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: June 30, 2020
    Assignee: Pharmacyclics LLC
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • Methods of preventing platelet activation
    Patent number: 10688109
    Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: June 23, 2020
    Assignee: Vanderbilt University
    Inventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
  • Methods of reducing apolipoprotein C-III
    Patent number: 10675263
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 9, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Transient protection of normal cells during chemotherapy
    Patent number: 10660896
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 26, 2020
    Assignee: GI Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • PRMT5 inhibitors and uses thereof
    Patent number: 10653693
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 19, 2020
    Assignees: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash
  • Intravenous administration of tramadol
    Patent number: 10646433
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 12, 2020
    Assignee: Revogenex Ireland Ltd.
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping
  • Methods for treating cancer
    Patent number: 10646464
    Abstract: Methods for treating advanced thymoma and thymic carcinoma in a subject comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (2-acetylnaphtho[2,3-b]furan-4,9-dione) as disclosed herein.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: May 12, 2020
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Youzhi Li, Wei Li, Matthew Hitron, Yuan Gao
  • Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma
    Patent number: 10632090
    Abstract: Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 28, 2020
    Inventors: Shil Kothari, Gary Troxel
  • Famciclovir and meloxicam combination therapy for functional somatic syndromes
    Patent number: 10632087
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and meloxicam.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 28, 2020
    Assignee: INNOVATIVE MED CONCEPTS, LLC.
    Inventor: William L. Pridgen
  • Method of inhibiting DYRK1B
    Patent number: 10633369
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: April 28, 2020
    Assignee: 4 SC AG
    Inventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
  • Intravenous administration of tramadol
    Patent number: 10624842
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HC given every 6 hours.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 21, 2020
    Assignee: Revogenex Ireland Ltd.
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping
  • Methods and compositions for treating schizophrenia
    Patent number: 10624875
    Abstract: The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 21, 2020
    Assignee: The Johns Hopkins University
    Inventors: Michela Gallagher, Ming Teng Koh
  • Intravenous administration of tramadol
    Patent number: 10617635
    Abstract: A method of treating pain, e.g., acute post-operative pain, by intravenously administering to a human patient(s) a dose of tramadol of about 45 mg to about 80 mg, based on tramadol hydrochloride, together with an intravenous dose of acetaminophen in an amount from about 500 mg to about 1000 mg, about every 6 hours.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 14, 2020
    Assignee: Revogenex Ireland Ltd.
    Inventor: Lucy Lu
  • Composition comprising decanal or as active ingredients for preventing hair loss or stimulating hair growth
    Patent number: 10617612
    Abstract: A composition for preventing hair loss or promoting hair growth comprising Decanal or pharmaceutically acceptable salt thereof as an active ingredient is provided. In particular, the composition relates to a quasi-drug, a cosmetic composition, a health functional food composition, and a pharmaceutical composition for preventing hair loss or promoting hair growth, which exhibits an excellent and stable effect on hair growth and hair growth, even while comprising a natural compound which has no side effect even in long-term administration in a chronic disease as an active ingredient.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: April 14, 2020
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventor: Tae Sun Park
  • Methods of reducing apolipoprotein C-III
    Patent number: 10610508
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 7, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Treatment of multiple sclerosis
    Patent number: 10610592
    Abstract: A composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. A method of treating neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and treating neurodegeneration. A method of reducing and/or eliminating symptoms of neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and reducing and/or eliminating the individual's symptoms of neurodegeneration. A method of reducing and/or eliminating lesions from neurodegeneration. A method of recovering mobility of an individual suffering from neurodegeneration.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 7, 2020
    Inventor: Fabrizio De Silvestri
  • Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
    Patent number: 10583145
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 10, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna